Myocardial Infarction, Stroke, and Death after Intravitreal Injection of Anti-VEGF in a Nationwide Study - PubMed
4 hours ago
- #Myocardial Infarction
- #Intravitreal Injection
- #Anti-VEGF
- Study assesses risk of myocardial infarction, stroke, and death after intravitreal injection (IVT) of anti-VEGF.
- Controlled cohort study in France (2010-2016) comparing 334,663 anti-VEGF IVT patients with 981,172 cataract surgery controls.
- Low occurrence (0.2%) of myocardial infarction, stroke, or death at 28 days in both groups.
- No increased risk observed in the IVT group (adjusted RR 0.96; 95% CI 0.88-1.05; P = 0.42).
- No additional risk found in patients with diabetes or history of stroke/myocardial infarction.
- Subgroup analysis showed similar results for ranibizumab (RR 0.97) and aflibercept (RR 0.82).
- Conclusion: Low overall risk of main outcomes post-IVT; no difference between aflibercept and ranibizumab.